Aim To systematically assess the clinical efficacy and safety of leflunomide for treating
psoriatic arthritis (PsA). Methods PubMed, Embase, and Cochrane Library databases were …

Introduction This study investigated the effectiveness of adalimumab treatment in improving
Work Productivity and Activity Impairment (WPAI) in patients with psoriatic arthritis (PsA) in …

Objective To examine trends in the use of systemic disease‐modifying antirheumatic drugs
(DMARD s) among patients with psoriatic arthritis (PsA) in the US. Methods Using claims …

Objectives To understand change in work productivity, activity impairment, quality of life
(QoL), and disease activity in patients with psoriatic arthritis (PsA) receiving anti-tumor …

Objectives This study aims to compare the clinical characteristics, disease activity, and
quality of life (QoL) of patients with psoriatic arthritis (PsA) who use biological and …

Introduction/objectives To evaluate changes in health-related quality of life (HRQoL) and
productivity following treatment with intravenous (IV) golimumab in patients with psoriatic …

Objectives PsA and AS are chronic diseases associated with significant morbidities.
National and international management guidelines include treatment with biologic therapies …

Objective. To evaluate the effect of access to and distance from rheumatology care on the
use of disease-modifying antirheumatic drugs (DMARD) in US veterans with inflammatory …

Objective: The aim of this study was to evaluate the impact of adherence to adalimumab on
all-cause work loss, healthcare resource utilization (HRU), and direct medical and indirect …

Psoriatic arthritis is a heterogeneous disease that can vary from a mild disease state to an
erosive and deformative state. 2 If left untreated, it can cause progressive joint damage …